Assenagon Asset Management S.A. Has $12.85 Million Stock Holdings in Glaukos Corporation $GKOS

Assenagon Asset Management S.A. boosted its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 1,206.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 157,545 shares of the medical instruments supplier’s stock after acquiring an additional 145,487 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.27% of Glaukos worth $12,848,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Norges Bank acquired a new position in Glaukos during the 2nd quarter worth $76,314,000. Primecap Management Co. CA boosted its stake in Glaukos by 50.0% during the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after buying an additional 609,523 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Glaukos by 56.5% in the 1st quarter. Alliancebernstein L.P. now owns 1,277,539 shares of the medical instruments supplier’s stock valued at $125,735,000 after buying an additional 461,386 shares in the last quarter. AustralianSuper Pty Ltd acquired a new position in Glaukos in the second quarter worth about $41,946,000. Finally, William Blair Investment Management LLC boosted its stake in Glaukos by 52.4% in the 2nd quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock valued at $117,347,000 after buying an additional 390,805 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Trading Up 2.5%

Shares of NYSE:GKOS opened at $116.04 on Friday. The business has a 50 day moving average of $94.57 and a 200-day moving average of $93.42. The stock has a market cap of $6.66 billion, a PE ratio of -75.35 and a beta of 0.69. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $163.71. The company has a quick ratio of 4.47, a current ratio of 5.20 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The firm had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business’s revenue for the quarter was up 38.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) EPS. As a group, equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the transaction, the director directly owned 34,905 shares in the company, valued at approximately $3,744,259.35. This represents a 12.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 19,340 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total value of $1,740,600.00. Following the completion of the sale, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at approximately $8,312,940. The trade was a 17.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 24,655 shares of company stock worth $2,310,025 over the last 90 days. Insiders own 5.80% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Truist Financial raised their price objective on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. upped their target price on shares of Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. The Goldman Sachs Group assumed coverage on Glaukos in a research report on Wednesday, October 1st. They set a “buy” rating and a $103.00 price target on the stock. UBS Group set a $165.00 price objective on shares of Glaukos in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $116.46.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.